Stearoyl-CoA desaturase-1 impairs the reparative properties of macrophages and microglia in the brain by Bogie, J.F.J. (Jeroen ) et al.
ARTICLE
Stearoyl-CoA desaturase-1 impairs the reparative
properties of macrophages and microglia in the brain
Jeroen F.J. Bogie1*, Elien Grajchen1*, Elien Wouters1, Aida Garcia Corrales1, Tess Dierckx1, Sam Vanherle1, Jo Mailleux1, Pascal Gervois2, Esther Wolfs2,
Jonas Dehairs3, Jana Van Broeckhoven1, Andrew P. Bowman4, Ivo Lambrichts2, Jan-A˚ke Gustafsson5,6, Alan T. Remaley7, Monique Mulder8,
Johannes V. Swinnen3, Mansour Haidar1, Shane R. Ellis4, James M. Ntambi9,10, Noam Zelcer11, and Jerome J.A. Hendriks1
Failure of remyelination underlies the progressive nature of demyelinating diseases such as multiple sclerosis. Macrophages
and microglia are crucially involved in the formation and repair of demyelinated lesions. Here we show that myelin uptake
temporarily skewed these phagocytes toward a disease-resolving phenotype, while sustained intracellular accumulation of
myelin induced a lesion-promoting phenotype. This phenotypic shift was controlled by stearoyl-CoA desaturase-1 (SCD1), an
enzyme responsible for the desaturation of saturated fatty acids. Monounsaturated fatty acids generated by SCD1 reduced the
surface abundance of the cholesterol efflux transporter ABCA1, which in turn promoted lipid accumulation and induced an
inflammatory phagocyte phenotype. Pharmacological inhibition or phagocyte-specific deficiency of Scd1 accelerated
remyelination ex vivo and in vivo. These findings identify SCD1 as a novel therapeutic target to promote remyelination.
Introduction
A major pathological hallmark of neuroinflammatory disorders
such as multiple sclerosis (MS) is the accumulation of periph-
erally derived macrophages and resident microglia within the
central nervous system (CNS; Ajami et al., 2011; Bogie et al.,
2014; Mildner et al., 2009). Until recently, these phagocytes
were mainly thought to boost lesion progression. Disease-
promoting effector functions include the release of inflamma-
tory and toxic mediators that negatively impact neuronal and
oligodendrocyte integrity (Nikic´ et al., 2011; Trapp et al., 1998),
internalization of the intact myelin sheath (Yamasaki et al., 2014),
and the presentation of CNS-derived antigens to autoreactive
T cells (McMahon et al., 2005). However, this notion has been
challenged in recent years, and it is now clear that phagocytes
also have disease-resolving functions in neurological disorders
(Grajchen et al., 2018). For example, clearance of damaged myelin
is essential to facilitate CNS repair (Miron et al., 2013; Ruckh
et al., 2012). Moreover, ingestion of myelin by phagocytes re-
shapes their phenotype to one that is typically associated with
wound healing and is accompanied by reduced expression of
inflammatory mediators (Bogie et al., 2011; Boven et al., 2006;
Hikawa and Takenaka, 1996). We recently found that this pro-
tective phenotype is closely linked to the activation of lipid-
responsive signaling pathways, such as the liver X receptor
(LXR) and peroxisome proliferator-activated receptor signaling
pathways (Bogie et al., 2012, 2013). At the same time, a number of
studies indicate that myelin-containing foam cells also display
inflammatory features (van der Laan et al., 1996; Wang et al.,
2015; Williams et al., 1994). To date, it remains unclear which
signals direct foam cells in the CNS to acquire a disease-
promoting or -resolving phenotype. Identifying the molecular
pathways that direct the phenotype of foamy phagocytes in the
CNS is essential for our understanding of lesion progression in
neurodegenerative disorders and for the development of re-
parative therapies.
Here, we report that sustained intracellular accumulation of
myelin counteracts the reparative phenotype of phagocytes in
demyelinating disorders. This phenotypic shift is orchestrated
by stearoyl-CoA desaturase-1 (SCD1), an enzyme that catalyzes
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the rate-limiting step in the conversion of saturated (SFA) into
mono-unsaturated fatty acids (MUFAs). We show that SCD1-
derived MUFAs induce inflammatory foam cell formation by
impairing ABCA1-mediated cholesterol efflux. Depletion of SCD1
in phagocytes prevents the myelin-induced phenotype shift and
promotes remyelination. Our findings highlight the importance
of fatty acid (FA) desaturation in controlling foamy phagocyte
function inMS and potentially other neurodegenerative disorders.
Results
Myelin overload skews phagocytes toward an
inflammatory phenotype
Phagocytes are the most abundant immune cells in active MS
lesions, and the majority of them show intracellular myelin
remnants (Grajchen et al., 2018). As cholesterol is a major con-
stituent of myelin, it represents an ideal parameter to define the
intracellular myelin load within foamy phagocytes. Accordingly,
by visualizing myelin-derived cholesterol, we found increased
free cholesterol (FC; filipin staining) and esterified cholesterol
(EC; Oil Red O [ORO] staining) in myelin-containing phagocytes
(mye-phagocytes) in active lesions in postmortem brain tissue of
MS patients (Fig. 1, A–D). In line with lesion expansion, actively
phagocytosing cells in the rim of MS lesions showed a lower
cholesterol burden as compared with those in the lesion center
that have accumulated myelin for a longer period of time (Fig. 1,
A–D). Phagocytes in the normal-appearing white matter (NAWM)
of MS patients and non-neurological controls showed no cho-
lesterol accumulation (Fig. 1, A–D; and Fig. S1, A and B).
Given the controversy around the phenotype of mye-
phagocytes (Grajchen et al., 2018), we next determined the
impact of the intracellular myelin load on the inflammatory
phenotype of phagocytes. For this purpose, mouse bone
marrow–derived macrophages (BMDMs), mouse microglia, and
human monocyte-derived macrophages (MDMs) were treated
for 24 or 72 h with myelin (mye24- or mye72-BMDMs/microglia/
MDMs; experimental design in Fig. S1 C). To validate the in-
tracellular accumulation of myelin, we first assessed the cho-
lesterol content of mye24- and mye72-phagocytes. Prolonged
incubation with myelin markedly increased the presence of
total cholesterol, FC, and EC in all phagocyte subsets (Fig. 1,
E–G). Given that in the lesion environment macrophages and
microglia are exposed to inflammatory mediators, the pheno-
type of mye-phagocytes was defined following stimulation with
the prototypical inflammatory stimulus LPS and disease-
relevant inflammatory cytokines IFN-G and IL-1B. Interest-
ingly, in parallel to increasing the intracellular cholesterol load,
prolonged uptake of myelin countered the initial less inflam-
matory phenotype of mye-phagocytes upon stimulation with
LPS (Fig. 2, A–C), while not influencing cell viability (Fig. S1 D).
Likewise, while short-term incubation with myelin induced a
less-inflammatory phenotype of IFN-G/IL-1B–stimulated MDMs,
BMDMs, and microglia, prolonged incubation with myelin
skewed these cells toward a more inflammatory phenotype (Fig.
S1 E). Moreover, akin to the in vitro experiments, myelin load
closely correlated with the phenotype of phagocytes within ac-
tive lesions in postmortem brain tissue of MS patients. Foamy
phagocytes in the lesion center, containing abundant intracel-
lular myelin remnants (Fig. 1, A–D), showed a more pronounced
immunoreactivity for the inflammatory markers CCR7 (Van
Raemdonck et al., 2019), CD32 (Kigerl et al., 2009), and IL-1B
compared with foamy phagocytes in the lesion rim that con-
tained less intracellular myelin (Fig. 2, D–I). Also, the density of
phagocytes expressing CCR7, CD32, and IL-1B was increased in
the lesion center compared with the lesion rim (Fig. 2, J–L).
Collectively, these findings indicate that sustained accumulation
of myelin skews macrophages and microglia toward an inflam-
matory phenotype.
SCD1 drives the inflammatory phenotype shift of
foamy phagocytes
Our previously reported transcriptomic analysis identified Scd1,
the rate-limiting enzyme in the conversion of SFA into MUFAs,
as one of the most potently induced genes in macrophages after
prolonged uptake of myelin (Bogie et al., 2012). SCD1 belongs to
the family of Δ9-FA desaturases (mouse; SCD1-4, human; SCD1
and 5), which exhibit different tissue and cell distribution pat-
terns (Flowers and Ntambi, 2008). Here, we found that myelin
exposure robustly increased themRNA expression of Scd1 but not of
the other Scd isoforms in BMDMs, and to a lesser extent also in
microglia and MDMs (Fig. 3 A). This increase in Scd1 mRNA was
accompanied by a higher SCD1 protein level (Fig. 3 B and Fig. S1 F). In
particular, cells with high granularity (side scatter [SSC]hi), corre-
sponding to cells that internalized large amounts of myelin, showed
the highest level of SCD1 (Fig. 3 B). Previous studies demonstrated
that SCD1 is a transcriptional target of LXRs through SREBP1C (Chu
et al., 2006; Zhang et al., 2014). In line with this, we find that LXRβ,
and not LXRα, was the predominant isoform to control SCD1 protein
level in BMDMs upon myelin exposure (Fig. S1 G).
To determine the desaturation level of FAs in mye-
phagocytes, a proxy for SCD1 activity, electrospray ionization
tandem mass spectrometry (ESI-MS/MS) analysis was per-
formed. Sustained accumulation of myelin in BMDMs reduced
the level of SFAs and increased that of unsaturated FAs (UFAs)
in intact phosphatidylcholine (PC; Fig. 3 C), which is the most
abundant phospholipid family in mammalian membranes. This
finding suggests that SCD1 activity is increased in phagocytes
after prolonged uptake of myelin. In support of this notion, gas
chromatography mass spectrometry (GC-MS) analysis of hy-
drolyzed FAs derived frommye72-BMDMs showed increased 16:
1/16:0 and 18:1/18:0 desaturation indices compared with control
cells (Fig. 3 D). Collectively, our findings show that myelin in-
ternalization increases SCD1 abundance and activity in phagocytes.
Given that foamy phagocytes are abundant in active lesions
of MS patients, we next determined whether myelin internali-
zation also increased the level and activity of SCD1 in phagocytes
in these lesions. Fluorescent double staining demonstrated that
the majority of IBA1+ phagocytes in the rim and center of active
MS lesions expressed SCD1 and that SCD1 was primarily ex-
pressed by IBA1+ phagocytes (Fig. 3, E and F; and Fig. S1, H and I).
A gradual increase of SCD1 intensity in IBA1+ cells was observed
toward the lesion center (Fig. 3 E). As phagocytes in the lesion
center have a higher cholesterol load compared with those in
the lesion rim, this finding suggests an association between
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sustained intracellular accumulation of myelin and SCD1 abun-
dance in active MS lesions. To define whether elevated SCD1
protein level was associated with increased SFA desaturation,
MUFA-containing PC lipid species were visualized in active MS le-
sions using matrix-assisted laser/desorption ionization-mass spec-
trometry imaging. We found an increased PC 36:2/PC 36:1 ratio
in lesions compared with adjacent NAWM (Fig. 3 G; individual
ion images and second active MS lesion are shown in Fig. S1,
J–L). Tandem mass spectrometry analysis confirmed the PC 36:
2 lipid species to consist primarily of two MUFA 18:1 fatty acyl
chains. As active SCD1 signaling results in the formation of 18:
1 fatty acyl chains, these findings are consistent with increased
desaturase activity within active lesions of MS patients.
As our data show that SCD1 expression coincides with an
increased inflammatory phenotype of phagocytes after pro-
longed uptake of myelin, we next determined if SCD1 is involved
in directing this phenotype. To test this, an SCD1-selective in-
hibitor was used (CAY10566; Chen et al., 2016). Consistent with
SCD1 inhibition, mye-BMDMs exposed to the SCD1 inhibitor
showed an increase in SFAs and a decrease in UFAs (Fig. S2 A).
Importantly, SCD1 inhibition prevented the inflammatory phe-
notypic shift associated with prolonged myelin uptake (Fig. 4 A),
and attenuated release of NO and TNF-A by mye72-BMDMs
(Fig. 4 B). An identical phenotype shift was observed using
BMDMs isolated from Scd1−/− mice (Fig. 4, A and B). Similar to
BMDMs, microglia and MDMs treated with the SCD1 inhibitor
Figure 1. Sustained exposure to myelin increases the intracellular cholesterol load in phagocytes. (A–D) Representative images and quantification of
ORO (EC) and filipin (FC) staining of active lesion in postmortem brain tissue of MS patients (n = 3 lesions from three different MS patients). Phagocyte EC and
FC load was determined by defining the cellular area covered by ORO+ and FC+ droplets. Scale bars, 500 µm (overview); 50 µm (inset). (E and F) Repre-
sentative images of ORO and filipin staining of mouse BMDMs, mouse microglia, and human MDMs treated with myelin for 24 or 72 h, or left untreated (Ctrl).
Scale bar, 30 µm. (G) Quantification of total cholesterol, FC, and EC in BMDMs (n = 7 wells), microglia (n = 5 wells), and MDMs (n = 7 wells) treated with myelin
for 24 or 72 h, or left untreated (Ctrl). Results are pooled from or representative of two (E–G) or three (A–D) independent experiments. Human MDM cultures
from seven donors were used (G). All data are represented as mean ± SEM. *, P < 0.05, **, P < 0.01, and ***, P < 0.001, one-way ANOVA.
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showed a decreased inflammatory response upon prolonged
myelin exposure (Fig. 4, C and D). Notably, inhibition of SCD1
activity did not impact the expression of neurotrophic factors in
all mye-phagocyte subsets (Fig. S2 B). These findings position
SCD1 as an important mediator of the inflammatory status of
myelin-phagocytosing macrophages and microglia.
Parallel to reducing the inflammatory status of mye-
phagocytes, SCD1 inhibition or genetic deficiency lowered
intracellular cholesterol load in all phagocyte subsets after pro-
longed myelin uptake (Fig. 4, E and F), a reduction that was not a
result of reduced viability or decreased phagocytic capacity (Fig.
S2, C and D). Transmission electron microscopy further dem-
onstrated that inhibition of SCD1 reduced the number of lipid
droplets within mye72-BMDMs without affecting their size (Fig.
S2, E–G). In contrast, myelin-containing organelles, comprising
lysosomes and endosomes, were significantly reduced in size in
Figure 2. Prolonged exposure to myelin promotes an inflammatory phagocyte phenotype. (A–C) mRNA expression of inflammatory factors in LPS-
stimulated human MDMs (n = 7 wells), mouse BMDMs (n = 5 wells), and mouse microglia (n = 6 wells) treated with myelin for 24 or 72 h, or left untreated
(dotted line, Ctrl). (D–L) Representative immunofluorescence images and quantification (MFI of CCR7, CD32, and IL-1B in phagocytes, and number of
phagocytes expressing CCR7, CD32, and IL-1B) of an active MS lesion stained with CCR7/CD68, CD32/IBA1, and IL-1B/IBA1 (n = 3 lesions from three different
MS patients). Scale bars, 500 µm (overview); 50 µm (inset). Results are pooled from or representative of two (B and C) or three (D–L) independent ex-
periments. Human MDM cultures from seven donors were used (A). All data are represented as mean ± SEM. *, P < 0.05, **, P < 0.01, and ***, P < 0.001,
unpaired Student’s t test (A–C), one-way ANOVA (G–L).
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mye72-BMDMs treated with the SCD1 inhibitor (Fig. S2, E–G).
These findings show that SCD1 inhibition promotes the pro-
cessing and potential clearance of myelin by phagocytes.
SCD1-derived FAs reduce ABCA1 surface abundance through
protein kinase C δ (PKCδ)
The above results indicate that SCD1 deficiency reduces intra-
cellular cholesterol levels in mye-phagocytes without affecting
their phagocytic capacity. Given the importance of lipid efflux in
controlling cellular cholesterol load, we next determined the
expression and activity of the cholesterol efflux transporter
ABCA1. Myelin uptake increased the mRNA expression of Abca1
in BMDMs, microglia, and MDMs, with mye72-phagocytes
showing the highest expression (Fig. 5 A). Counterintuitively,
while short-term treatment with myelin increased surface
abundance of ABCA1, mye72-BMDMs and -microglia had reduced
Figure 3. Myelin internalization increases SCD1 abundance and activity in phagocytes. (A) mRNA expression of Scd isoforms in myelin-treated BMDMs,
microglia, and MDMs (24 and 72 h, n = 6 wells). Dotted line represents untreated cells (Ctrl). (B) Flow-cytometric analysis of SCD1 abundance in myelin-treated
BMDMs, microglia, and MDMs (24 and 72 h, n = 6 wells). Side scatter measurement was used to identify phagocytes that internalized little (SSClo) and large
(SSChi) amounts of myelin. Dotted line represents untreated cells (Ctrl). (C) ESI-MS/MS–based lipidomics analysis of intact PC in myelin-treated BMDMs (24
and 72 h, n = 2 wells). (D) GC/MS analysis of the methyl esters of FAs hydrolyzed from untreated and myelin-treated BMDMs (72 h). Desaturation indices were
determined by calculating the 16:1/16:0 and 18:1/18:0 ratios (n = 4 wells). (E and F) Representative images and quantification (MFI) of SCD1 in lesional
phagocytes. Active MS lesions were stained for SCD1/IBA1 (n = 3 lesions from three different MS patients). Scale bar, 50 µm. (G)Mass spectrometry image of
the ratio of intact PC lipid species and corresponding ORO staining of an active MS lesion. The PC 36:2/PC 36:1 ratio was calculated based on intensity images
of individual PC lipid species (Fig. S1 J). A second active MS lesion is shown in Fig. S1, K and L. Scale bar, 500 µm. Results are pooled from or representative of
two (A–D and G) or three (E and F) independent experiments. Human MDM cultures from six donors were used (A). All data are represented as mean ± SEM. *,
P < 0.05, **, P < 0.01, and ***, P < 0.001, unpaired Student’s t test (A, B, and D), one-way ANOVA (E).
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surface levels of ABCA1 (Fig. 5, B and C). MDMs showed a trend
toward decreased surface ABCA1 levels after prolonged myelin
uptake (Fig. 5 D). Interestingly, SCD1 inhibition and genetic
deficiency prevented the reduction in surface ABCA1 levels on
all mye72-phagocyte subsets (Fig. 5, B–D). A similar reduction in
ABCA1 levels upon prolonged exposure to myelin was observed
in HeLa cells expressing a functional human ABCA1-GFP fusion
protein (HeLa-ABCA1gfp, Fig. S3 A). HeLa cells efficiently inter-
nalized and processed myelin (Fig. S3, B–D). Consistent with
surface ABCA1 levels, cholesterol efflux toward the ABCA1-
dependent lipid acceptor apoA-I was attenuated in mye72-
phagocytes in an SCD1-dependent manner (Fig. 5, E–G). To
identify which FAs are responsible for impaired ABCA1-
mediated cholesterol efflux, the FA profile of mye-BMDMs was
measured. Myelin accumulation not only increased intracellular
levels of palmitoleic acid (16:1) and oleic acid (18:1), in line with
elevated SCD1 activity, but also markedly increased gondoic acid
(20:1) and nervonic acid (24:1; Fig. S3, E and F). The latter finding
indicates active elongation of SCD1-derived FAs. By using HeLa-
ABCA1gfp cells, we further show that palmitoleic, oleic, gondoic,
and erucic acid (22:1) reduced total ABCA1 abundance upon in-
ternalization (Fig. S3, G and H). To test whether accumulation of
these FA species reduces ABCA1-mediated cholesterol efflux,
BMDMs were treated with each of the aforementioned FAs. We
found that oleic, gondoic, and nervonic acid reduced ABCA1-
mediated cholesterol efflux, while palmitoleic acid and erucic
acid did not have an effect (Fig. 5 H). In summary, these find-
ings indicate that SCD1-derived MUFAs reduce the capacity of
mye-phagocytes to efflux cholesterol via ABCA1.
Interestingly, analysis of human postmortem brain tissue
demonstrated that surface ABCA1 abundance also inversely
correlated with SCD1 protein level and intracellular lipid load
within phagocytes in MS lesions. Whereas phagocytes in the
lesion rim displayed a clear surface ABCA1 staining pattern,
phagocytes in the lesion center showed a predominant intra-
cellular localization of ABCA1, as well as an overall reduced level
of ABCA1 (Fig. 5, I–L). This ABCA1 expression pattern closely
corresponds to the abundant presence of cholesterol and in-
creased magnitude of SCD1 expression within phagocytes in the
lesion center compared with the lesion rim (Fig. 1, A–D; and
Fig. 3, E and F).
The discrepancy between ABCA1 mRNA and protein levels in
our in vitro experiments suggests that post-transcriptional
modifications underlie the loss of surface ABCA1 abundance on
phagocytes after prolonged exposure to myelin (Fig. 5, A–D). As
MUFAs are reported to decrease ABCA1 abundance on the cell
surface in a PKCδ-dependent manner (Sun et al., 2003; Wang
and Oram, 2002, 2007; Yang et al., 2010), we reasoned that PKCδ
might control ABCA1 surface level, cholesterol load, and the
phenotype of mye-phagocytes as well. By using the PKCδ
inhibitor rottlerin (Gschwendt et al., 1994), we show that in-
hibition of PKCδ increased surface abundance of ABCA1 on
Figure 4. SCD1 controls the inflammatory phenotype shift of mye-phagocytes. (A) mRNA expression of inflammatory mediators in LPS-stimulated WT,
Scd1−/−, and SCD1 inhibitor-treated BMDMs exposed to myelin for 72 h (n = 5 wells). (B)NO and TNF-A concentration in culture supernatants of LPS-stimulated
WT, Scd1−/−, and SCD1 inhibitor-treated mye72-BMDMs (n = 5 wells). (C and D) mRNA expression of inflammatory mediators in LPS-stimulated mouse mi-
croglia (n = 6 wells) and human MDMs (n = 8 wells) exposed to myelin and an SCD1 inhibitor for 72 h. (E and F) Quantification of total cholesterol in WT,
Scd1−/−, and SCD1 inhibitor-treated mye72-BMDMs (E, n = 6 wells), and SCD1-inhibitor treated mye72-microglia (F, n = 6 wells) and -MDMs (F, n = 8 wells).
Results are pooled from two independent experiments (A–C, E, and F). HumanMDM cultures from four donors were used (D and F). All data are represented as
mean ± SEM. *, P < 0.05, **, P < 0.01, and ***, P < 0.001, one-way ANOVA (A, B, and E), unpaired Student’s t test (C, D, and F).
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mye72-phagocytes but not mye24-phagocytes (Fig. 6 A and Fig.
S3 I). Elevated ABCA1 surface levels on mye72-phagocytes were
accompanied by a reduction in cellular cholesterol load (Fig. 6,
B–E) and a decreased expression of inflammatory mediators
(Fig. 6, F–H). Collectively, these findings provide evidence that
PKCδ controls lipid efflux and the inflammatory status of
mye72-phagocytes.
SCD1-mediated loss of ABCA1 leads to the accumulation of
inflammatory FC
Loss of ABCA1 drives phagocytes toward an inflammatory phe-
notype by promoting the accumulation of inflammatory FC (Tall
and Yvan-Charvet, 2015; Yvan-Charvet et al., 2008). By using
Abca1−/− BMDMs (Fig. S3, J and K), we found that loss of ABCA1
also accelerated the accumulation of FC in mye-BMDMs (Fig. 7
A). Given that prolonged exposure to myelin significantly re-
duced the viability of Abca1−/− BMDMs (Fig. S3 L), subsequent
experiments were performed using Abca1−/− mye24-BMDMs.
Interestingly, Abca1−/− BMDMs acquired an inflammatory phe-
notype already upon short-term incubation with myelin (mye24-
BMDMs; Fig. 7 B). To establish a causal link between SCD1,
ABCA1, and the inflammatory phenotype of mye-BMDMs,
Abca1−/− mye24-BMDMs were treated with the SCD1 inhibitor.
In the absence of ABCA1, inhibition of SCD1 did not attenuate
the inflammatory phenotype of mye24-BMDMs, nor did it de-
crease the intracellular FC load (Fig. 7, C and D). These results
Figure 5. Myelin uptake decreases ABCA1 surface levels in an SCD1-dependent manner. (A)mRNA expression of Abca1 in BMDMs (n = 5 wells), microglia
(n = 6 wells), and MDMs (n = 6 wells) treated with myelin for 24 and 72 h. Dotted line represents untreated cells (Ctrl). (B–G) Surface ABCA1 abundance (n = 5
or 6 wells) and relative capacity to efflux cholesterol (n = 6 wells) of WT, Scd1−/−, and SCD1 inhibitor-treated BMDMs exposed to myelin for 24 or 72 h (B and E),
and mye-microglia (C and F) and mye–MDM (D and G) treated with the SCD1 inhibitor. Dotted line represents untreated cells (Ctrl). (H) Cholesterol efflux
capacity of BMDMs treated with different MUFAs (50 µM; n = 3 wells). (I–L) Representative immunofluorescence images and quantification (MFI of ABCA1 in
phagocytes and percentage of phagocytes expressing ABCA1 on the cell surface within the phagocyte pool) of an active MS lesion stained for ABCA1/CD68 (n = 3
lesions from three different MS patients). Scale bars, 50 µm (I); 20 µm (L). Results are pooled from or representative of two (A–H) or three (I–L) independent
experiments. Human MDM cultures from six donors were used (A, D, and G). All data are represented as mean ± SEM. *, P < 0.05, **, P < 0.01, and ***, P <
0.001, unpaired Student’s t test (A and H), one-way ANOVA (B–G, J, and K).
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suggest that SCD1 skews mye-phagocytes toward an inflam-
matory phenotype by reducing ABCA1 surface levels and efflux
capacity. In addition, they suggest that accumulation of FC due
to a decrease in ABCA1 underlies the induction of this inflam-
matory phenotype in mye72-phagocytes. To test this, mye72-
phagocytes were depleted of FC using methyl-β-cyclodextrin
(MβCD). MβCD (2.5% m/v) efficiently removed FC without
affecting the level of EC and cell viability (Fig. S3, M and N).
Importantly, MβCD reduced the inflammatory phenotype of
Abca1−/−mye24-BMDMs and all mye72-phagocyte subsets (Fig. 7,
E–H). The latter experiments demonstrate that removal of FC is
sufficient to block the induction of an inflammatory phenotype
Figure 6. Myelin uptake impacts the metabolic and inflammatory phenotype of phagocytes in a PKCδ-dependent manner. (A) Surface ABCA1
abundance on myelin-treated mouse BMDMs (n = 5 wells), mouse microglia (n = 6 wells), and human MDMs (n = 4 wells) exposed to rottlerin (PKCδ inhibitor)
or vehicle. (B–E) Representative images and quantification of ORO (EC) and filipin (FC) staining of untreated phagocytes (Ctrl) and mye72-phagocytes treated
with rottlerin or vehicle (n = 4 wells). Scale bar, 20 µm. (F–H) mRNA expression of inflammatory mediators in LPS-stimulated mye72-BMDMs (n = 11 wells),
-microglia (n = 6), and -MDMs (n = 4 wells) treated with rottlerin or vehicle. Results are pooled from or representative of two (A–E, G, and H) or three (F)
independent experiments. Human MDM cultures from four donors were used (A–E and H). All data are represented as mean ± SEM. *, P < 0.05, **, P < 0.01,
and ***, P < 0.001, unpaired Student’s t test (A, F, G, and H), one-way ANOVA (D and E).
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of phagocytes upon sustained exposure to myelin. Collectively,
our findings show that accumulation of FC due to reduced
surface ABCA1 abundance underlies the inflammatory pheno-
type shift of mye-phagocytes.
SCD1 inhibition promotes remyelination in ex vivo organotypic
cerebellar brain slices
Remyelination is a regenerative process by which myelin
sheaths are restored to demyelinated axons (Franklin and
Ffrench-Constant, 2008). Ample evidence indicates that a re-
duced inflammatory burden favors remyelination (Cantuti-
Castelvetri et al., 2018; Karamita et al., 2017; Lan et al., 2018;
Makinodan et al., 2016; Vela et al., 2002). Given that SCD1 in-
hibition and deficiency suppressed the inflammatory status
of phagocytes after prolonged myelin incubation, we reasoned
that abrogation of SCD1 activity could be a therapeutic target to
promote remyelination. Remyelination was first studied using
ex vivo cerebellar brain slices demyelinated with lysolecithin
(experimental design in Fig. S4 A). In agreement with our
in vitro findings, SCD1 inhibition significantly reduced phago-
cyte cholesterol load and the inflammatory burden in remyeli-
nating cerebellar brain slices (Fig. 8, A–C). Accordingly, F4/80+
Figure 7. Accumulation of inflammatory FC underlies the SCD1-induced phenotype shift. (A) Quantification of FC in WT and Abca1−/− BMDMs treated
with myelin for 24 or 72 h (mye24- or mye72-BMDMs), or left untreated (Ctrl, n = 5 wells). (B) mRNA expression of inflammatory mediators in LPS-stimulated
WT and Abca1−/− mye24-BMDMs (n = 6 wells). Dotted line represents untreated BMDMs (Ctrl). (C) mRNA expression of inflammatory mediators in LPS-
stimulated Abca1−/− mye24-BMDMs treated with an SCD1 inhibitor or vehicle (n = 5 wells). (D) Quantification of FC in Abca1−/− mye24-BMDMs treated with a
selective SCD1 inhibitor or vehicle (n = 4 wells). (E)mRNA expression of inflammatory mediators in LPS-stimulated Abca1−/−mye24-BMDMs treated withMβCD
(2.5% m/v) or vehicle (n = 6 wells). (F–H)mRNA expression of inflammatory mediators in LPS-stimulated mye72-BMDMs (n = 6 wells), -microglia (n = 6 wells)
and -MDMs (n = 4 wells) treated with MβCD or vehicle. Results are pooled from two independent experiments (A–G). Human MDM cultures from four donors
were used (H). All data are represented as mean ± SEM. *, P < 0.05, **, P < 0.01, and ***, P < 0.001, unpaired Student’s t test (A–H).
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microglia showed decreased NOS2 immunoreactivity in slices
exposed to the SCD1 inhibitor (Fig. 8, D and E), and a reduced
concentration of NO was found in the supernatant of these slices
(Fig. 8 F).While astrocytes are reported to produce inflammatory
mediators such as NO (Liddelow and Barres, 2017), SCD1 inhi-
bition did not change Nos2 mRNA expression in control and
myelin-treated astrocytes in vitro (Fig. 8 G), corresponding to
the inability of myelin to increase Scd1 expression in these cells
(Fig. 8 H). In fact, prolonged myelin exposure reduced Scd1
mRNA expression in astrocytes. Finally, fluorescence staining
demonstrated increased colocalization of myelin (myelin basic
protein; MBP) and axons (neurofilament) in brain slices treated
with the SCD1 inhibitor (Fig. 8, D and I). Three-dimensional
reconstruction of these sections confirmed more efficient axo-
nal myelination in slices treated with the SCD1 inhibitor
(Fig. 8 D; Peng et al., 2014). These findings show that inhibition
of SCD1 promotes myelination of demyelinated axons, and are
consistent with the notion that a less inflammatory phagocyte
phenotype underlies the repair-promoting effect of SCD1 inhibition.
Phagocyte-specific Scd1 deficiency stimulates remyelination
in vivo
To evaluate the significance of these findings in vivo, the
cuprizone-induced de- and remyelination model was induced in
Figure 8. SCD1 inhibition stimulates remyelination in an ex vivo cerebellar brain slice model. (A and B) Representative images and quantification (lipid
load defined as percent area covered in lipid droplets of the total brain slice area) of ORO (EC) staining of cerebellar brain slices treated with an SCD1 inhibitor
or vehicle (n = 3 slices). Scale bars, 500 µm (overview); 50 µm (inset). (C)mRNA expression of inflammatory mediators in cerebellar brain slice cultures treated
with an SCD1 inhibitor or vehicle (n = 4 slices). (D) Representative immunofluorescence images of brain slice cultures treated with vehicle or an SCD1 inhibitor
and stained for NOS2/F4/80+ (n = 3 slices; scale bar, 50 µm) and MBP/neurofilament (n = 3 slices; scale bar, 50 µm; orthogonal and three-dimensional
reconstruction). (E)Quantification of NOS2 abundance (MFI) in F4/80+ phagocytes in brain slices treated with vehicle or an SCD1 inhibitor (n = 3 slices). (F) NO
concentration in culture supernatants of brain slices treated with an SCD1 inhibitor or vehicle (n = 4 slices). (G and H) mRNA expression of Nos2 and Scd1 in
LPS-stimulated control and myelin-treated (24 h and 72 h) mouse astrocytes cultures (n = 3 wells). Dotted line represents control cultures (H). (I) Percentage of
MBP+ NF+ axons out of total NF+ axons in brain slices treated with the SCD1 inhibitor or vehicle (n = 4 slices). Results are pooled from or representative of three
(A, B, D, E, G, and H) or four (C, F, I, and J) independent experiments. Each replicate represents one brain slice. All data are represented as mean ± SEM. *, P <
0.05, **, P < 0.01, and ***, P < 0.001, unpaired Student’s t test (B, C, E, F, H, and I), one-way ANOVA (G).
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phagocyte-specific Scd1−/− mice (experimental design in Fig. S4
B). Cuprizone feeding leads to reproducible toxic demyelination
in distinct brain regions such as the corpus callosum (CC).
Cessation of cuprizone administration results in spontaneous
remyelination. Targeted depletion of Scd1 in macrophages and
microglia was achieved by crossing Scd1fl+/+ mice with LysMCre+/−
mice. SCD1 ablation was validated by immunoblotting (Fig. S4
C). After 6 wk of cuprizone treatment, demyelination was ob-
vious in the CC of both WT and Scd1fl+/+LysMCre+/− mice, as de-
termined by MBP staining and g-ratio analysis (the ratio of the
inner axonal diameter to the total outer diameter; Fig. 9, A–C).
1 wk after termination of cuprizone feeding, Scd1fl+/+LysMCre+/−
mice displayed an increased MBP reactivity and a decreased
g-ratio in the CC compared with WT mice, indicating that Scd1
deficiency in phagocytes promotes remyelination (Fig. 9, A–C).
In particular, small diameter axons showed thicker myelin
sheaths in Scd1fl+/+LysMCre+/− mice as compared with control
mice (Fig. 9 D). Enhanced remyelination in Scd1fl+/+LysMCre+/−
mice was associated with a reduced inflammatory burden in the
CC following demyelination (6wk) but not during remyelination
(6+1 wk; Fig. 9, E and F). The latter finding can be explained by
the relative absence of phagocytes in both WT and
Scd1fl+/+LysMCre+/− mice following 1 wk remyelination (Fig. S4, D
and E). No differences were observed in the expression of the
neurotrophic factors tumor growth factor β (Tgfb), ciliary neu-
rotrophic factor (Cntf), and insulin growth factor 1 (Igf1; Fig. S4, F
and G). Interestingly, Scd1fl+/+LysMCre+/− mice showed decreased
cholesterol load in the CC and within phagocytes after demye-
lination and during remyelination (Fig. 9, G–I). This finding
suggests that internalized myelin is more efficiently processed
in Scd1fl+/+LysMCre+/− mice. In support of this notion,
Scd1fl+/+LysMCre+/− mice showed a higher ABCA1 abundance in
the CC both after demyelination and during remyelination
(Fig. 9, G and J). Importantly, similar effects on remyelination
(Fig. S5, A–D), inflammation (Fig. S5, E and F), lipid processing
(Fig. S5, G–K), and the expression of neurotrophic factors (Fig.
S5, L and M) were observed in whole-body Scd1−/− mice. These
data show that SCD1 deficiency enhances remyelination by
promoting the reparative properties of phagocytes. Collec-
tively, our results identify SCD1 as a novel therapeutic target to
promote remyelination.
Discussion
Phagocytes display tremendous diversity and plasticity in vivo, a
reflection of dynamic changes in intracellular and extracellular
signals (Sica and Mantovani, 2012). Also within MS lesions, di-
vergent phagocyte activation states coexist in close proximity
(Boven et al., 2006; Vogel et al., 2013). With respect to mye-
phagocytes, some studies reported anti-inflammatory (M2-
like) features (Bogie et al., 2011, 2012, 2013; Boven et al., 2006;
Kroner et al., 2014; Liu et al., 2006), whereas others reported no
effect at all (Glim et al., 2010), or even an inflammatory (M1-
like) activation status (Cantuti-Castelvetri et al., 2018; van der
Laan et al., 1996; Williams et al., 1994). Our data now indicate
that the intracellular myelin load controls the phenotypes that
phagocytes display in MS lesions. Sustained internalization of
myelin skewed phagocytes toward an inflammatory phenotype
that suppressed CNS repair. We further define an intertwined
relationship between FA metabolism and this phenotype shift.
SCD1, the rate-limiting enzyme in FA desaturation, was found to
control the inflammatory phenotype shift of myelin phagocy-
tosing macrophages and microglia by reducing reverse choles-
terol transport and promoting the intracellular accumulation of
inflammatory cholesterol. Findings from this study explain, at
least in part, the progressive nature that MS lesions display and
argue for SCD1 inhibition as a promising new therapeutic
strategy in MS and other demyelinating diseases.
In demyelinating disorders, foamy phagocytes accumulate a
large amount of cytosolic lipid droplets consisting of an inert
storage pool of EC (Chang et al., 2006). Based on our findings, we
state that esterification of myelin-derived cholesterol, which is
predominantly present in its free form in myelin (Saher and
Stumpf, 2015), ensues to protect mye-phagocytes from FC-
induced toxicity. An increase in SCD1 activity likely provides
mye-phagocytes initially with a readily available pool of MUFAs
to esterify internalized myelin-derived FC. In this context, pal-
mitoleate and oleate, the end products of SCD1 desaturase ac-
tivity, make up the bulk of FAs in cholesterol esters (Miyazaki
et al., 2000). However, we also found that continuous SCD1
activity skews mye-phagocytes toward an inflammatory phe-
notype. With time, SCD1-derivedMUFAs reduced the capacity of
phagocytes to dispose of intracellular cholesterol by decreasing
surface ABCA1 abundance in a PKCδ-dependent manner. In line
with our findings, previous studies defined that MUFAs can
destabilize ABCA1 and inhibit ABCA1-mediated cholesterol ef-
flux (Sun et al., 2003; Wang and Oram, 2002, 2007; Yang et al.,
2010). It remains unclear why MUFAs formed by SCD1 are with
time no longer used for cholesterol esterification. In particular,
our findings indicate that prolonged uptake of myelin by
phagocytes markedly increases the cytosolic accumulation of FC.
We did not observe alterations in the expression of acyl-CoA:
cholesterol acyltransferases or find any morphological in-
dications of ER stress (data not shown), suggesting that ineffi-
cient cholesterol esterification or a dysfunctional ER do not
underlie the build-up of MUFAs. However, an inability of FC to
traffic to the ER and a consequent accumulation of FC in the
endosomal and lysosomal compartments may explain the in-
cessant increase in SCD1 activity in myelin overloaded phag-
ocytes. With respect to the latter, aging was recently found to
accelerate the accumulation of myelin in phagocytes, which
resulted in lysosomal accumulation of FC (Cantuti-Castelvetri
et al., 2018). Similar, we observed an increase in the size and
number of myelin-containing organelles enclosing unprocessed
myelin debris in phagocytes exposed to myelin for a prolonged
period of time. Studies focusing on the cellular trafficking and
compartmentalization of FC in mye-phagocytes are necessary to
certify this hypothesis.
We provide evidence that pharmacological SCD1 inhibition
and whole-body or phagocyte-specific Scd1 deficiency accelerate
remyelination. Enhanced remyelination was associated with a
decreased cholesterol load and elevated ABCA1 protein levels.
These findings strongly suggest that SCD1-induced inhibition of
cholesterol efflux suppresses the reparative properties of mye-
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phagocytes in vivo. In line with our results, defective cholesterol
clearance in mye-phagocytes was recently found to limit re-
myelination in the aged CNS (Cantuti-Castelvetri et al., 2018).
Ample evidence indicates that phagocytes drive remyelination
by producing neurotrophic factors such as IGF1, TGF-B, and
CNTF (Diemel et al., 2004; Kotter et al., 2005; Miron et al., 2013).
Here, we did not detect changes in the expression of these me-
diators in mye-phagocyte cultures and cuprizone animals lack-
ing active SCD1 signaling. However, in all used models enhanced
remyelination was closely associated with a reduced expression
of inflammatory mediators. Given the inhibitory impact of
TNF-A, IL-1B, NO, and IL-6 on remyelination (Cantuti-Castelvetri
et al., 2018; Karamita et al., 2017; Lan et al., 2018; Makinodan
et al., 2016; Vela et al., 2002), it is tempting to speculate that
the reduced inflammatory burden enhanced remyelination in
our models. Yet few studies defined that inflammation can also
stimulate remyelination by promoting the accumulation, pro-
liferation, and differentiation of oligodendrocyte precursor
cells (Arnett et al., 2001; Mason et al., 2001). Thus, while SCD1
inhibition accelerates remyelination and reduces inflammation
in our ex vivo and in vivo models, a causal link remains to be
determined.
Aside from divergent anatomical niches (Ajami et al., 2011;
Mildner et al., 2007), an increasing number of studies indicate
that macrophages and microglia differ in their ontogeny, de-
velopment, and function (Chrast et al., 2011; Goldmann et al.,
2016). A comparison of the transcriptomes demonstrated that
microglia express a unique cluster of transcripts encoding pro-
teins that sense endogenous ligands (Hickman et al., 2013). In
agreement, microglia show an enhanced capacity to internalize
myelin as compared with peripheral macrophages (Bogie et al.,
2017; Durafourt et al., 2012; Healy et al., 2016). Despite these
differences, we show that both phagocyte subsets change their
phenotype in a similar fashion upon myelin internalization
in vitro. Similar, as LysMCre targets macrophages and microglia
(Derecki et al., 2012; Ros-Bernal et al., 2011), enhanced re-
myelination and reduced inflammation in the CC of
Scd1fl+/+LysMCre+/− likely reflect the impact of SCD1 on both
foamy macrophages and microglia in vivo. Further support for
involvement of microglia in this process derives from the ex-
periments using the cerebellar brain slice model, which lacks
peripheral macrophages altogether. While astrocytes can
internalize myelin and display functional divergent phenotypes
(Liddelow and Barres, 2017; Ponath et al., 2017), SCD1 inhibition
did not affect the inflammatory phenotype of control and
myelin-treated astrocytes, nor did prolonged myelin exposure
increase Scd1 expression. The inability of sustained myelin in-
ternalization to increase Scd1 expression in astrocytes merits
further investigation. Collectively, our data indicate that SCD1
hampers the reparative of features of foamy phagocytes in
demyelinating lesions.
While SFAs are considered to promote the inflammatory
status of phagocytes (Anderson et al., 2012; Camell and Smith,
2013), UFAs are mainly known for their anti-inflammatory
properties (Camell and Smith, 2013; Souza et al., 2017). Para-
doxically, we find that pharmacological and genetic inhibition of
Scd1 alleviates the inflammatory status of mye72-phagocytes,
despite decreasing the desaturation index. Through a combina-
tion of successive elongation and desaturation reactions, a va-
riety of MUFAs and poly-unsaturated FAs can be formed from
SCD1-derived FAs. It remains to be determined which of these
UFAs are more pro- or anti-inflammatory in mye-phagocytes.
Moreover, the inflammatory outcome of changes in the level of
particular UFAs in phagocytes may be context-dependent. For
example, ABCA1 destabilization by UFAs is more likely to be-
come inflammatory in phagocytes that rely on lipid efflux to
protect themselves from the excessive accumulation of FC, such
as the mye-phagocytes described in this study. In support of this
notion, ABCA1 deficiency in nonlipid-loaded macrophages in-
duces a pro-angiogenic phenotype, characterized by a reduced
expression of inflammatory mediators (Sene et al., 2013). In
addition, given that SCD1 deficiency exacerbates inflammation
in acute colitis and atherosclerosis models (Chen et al., 2008;
MacDonald et al., 2009), changes in particular UFAs may impact
inflammation differently in the context of peripheral and
myelin-related disorders.More research is warranted to identify
culprit UFAs and further unravel the molecular mechanisms
that underlie the inflammatory impact of SCD1 on the phenotype
of mye-phagocytes.
Remyelination is a complex process that requires an intimate
interplay between myelin-forming cells and immunity. Clear-
ance of myelin debris by phagocytes is a critical step in the re-
myelination process. It not only permits the maturation of
oligodendrocyte progenitor cells but also skews phagocytes
Figure 9. Phagocyte-specific Scd1 deficiency improves remyelination in the cuprizone model. (A) Representative images of immunofluorescence MBP
staining and transmission electron microscopy analysis of CC from WT (Scd1fl−/−LysMCre+/− and Scd1fl+/+LysMCre−/−) and Scd1fl+/+LysMCre+/− mice after
cuprizone-induced demyelination (6 wk) and subsequent remyelination (6+1 wk). The outer border of the CC is demarcated by the dotted line. Scale bars,
100 µm (MBP staining); 2 µm (transmission electron microscopy). (B)Quantification of the remyelination efficacy (calculated by dividing the percent myelination
at 6+1 wk by the percent myelination at 6 wk using the MBP staining) in CC fromWT (6 wk, n = 11 animals; 6+1 wk, n = 10 animals) and Scd1fl+/+LysMCre+/− mice
(6 wk, n = 7 animals; 6+1 wk, n = 6 animals). (C and D) Analysis of the g-ratio (the ratio of the inner axonal diameter to the total outer diameter) and g-ratio as a
function of axon diameter in CC from WT (6 wk, n = 4 animals; 6+1 wk, n = 8 animals) and Scd1fl+/+LysMCre+/− mice (6 wk, n = 4 animals; 6+1 wk, n = 4 animals).
(E and F)mRNA expression of inflammatorymediators in CC ofWT (n = 10 or 11 animals, see B) and Scd1fl+/+LysMCre+/−mice (n = 6 or 7 animals, see B) after 6 wk
and 6+1 wk. Gene expression was corrected for the number of F4/80+ phagocytes. (G) Representative images of ORO (EC) and immunofluorescence ABCA1
staining of CC from WT (n = 10 or 11 animals, see B) and Scd1fl+/+LysMCre+/− (n = 6 or 7 animals, see B) mice after 6 wk and 6+1 wk. Scale bar, 100 µm. (H and I)
Quantification of ORO staining (lipid load defined as percent ORO+ area of total CC area [H] and lipid load corrected for the number of F4/80+ macrophages [I])
and ABCA1 staining (% ABCA1+ area of total CC area) of CC fromWT (n = 10 or 11 animals, see B) and Scd1fl+/+LysMCre+/− (n = 6 or 7 animals, see B)mice after 6 wk
and 6+1 wk. AU, arbitrary unit. All replicates were biologically independent. All data are represented as mean ± SEM. *, P < 0.05, **, P < 0.01, and ***, P < 0.001,
unpaired Student’s t test (B, E, and F), one-way ANOVA (C, H, I, and J).
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toward a reparative phenotype. Here, we show that sustained
intracellular accumulation of myelin debris inhibits the repar-
ative features of phagocytes and identifies the SCD1 signaling
axis as a crucial driver of this phenotype shift. SCD1 inhibitors
are already regarded as promising therapeutics for the treat-
ment of skin disorders, metabolic syndrome, and cancer (Uto,
2016). Our data now indicate that they could also confer thera-
peutic benefit in demyelinating disorders such as MS.
Materials and methods
Antibodies
The following antibodies were used for immunoblotting: anti-
SCD1 (1:1,000, cat. no. 2438S, Cell Signaling Technology), anti-
ABCA1 (1:1,000; Lee et al., 2005), and anti-actin (1:5,000, cat. no.
sc-47778, Santa Cruz Biotechnology). Appropriate HRP-
conjugated secondary antibodies for immunoblotting were
purchased from Dako and Cell Signaling Technology. The fol-
lowing antibodies were used for flow cytometry: anti-SCD1
(1:200, cat. no. ab19862, Abcam) and anti-ABCA1 (1:400, cat.
no. NB400-105, Novus Biologicals). The following antibodies
were used for immunofluorescence: anti-SCD1 (1:250, cat.
no. ab19862, Abcam), anti-CCR7 (1:100, cat. no. ab32527, Abcam),
anti-CD32 (1:500, cat. no. ab23336, Abcam), anti-IL1B (1:100, cat.
no. 12242, Cell Signaling Technology), anti-NOS2 (1:100, cat. no.
ab15323, Abcam), anti-NF (1:1,000, cat. no. ab8135, Abcam), anti-
IBA1 (1:500, cat. no. 019-19741, Fujifilm), anti-CD68 (1:100, cat.
no. 14-0688, Invitrogen), anti-MBP (1:250, cat. no. MAB386,
Millipore), anti-F4/80 (1:100, cat. no. MCA497G, Bio-Rad), and
anti-ABCA1 (1:200, cat. no. NB400-105, Novus Biologicals). Ap-
propriate secondary antibodies for flow cytometry and immu-
nofluorescence were purchased from Invitrogen.
Mice
Scd1-deficient (Scd1−/−) mice and mice having the third exon of
the Scd1 gene flanked by loxP sites (Scd1fl+/+) are described in
previous studies (Miyazaki et al., 2001, 2007). Both mouse
strains were backcrossed at least 10 times with C57BL/6J mice.
Mice having their 45–46th exon of the Abca1 gene flanked by loxP
sites (Abca1fl+/+) were kindly provided by J.S. Parks (Department
of Pathology/Section on Lipid Sciences, Wake Forest School of
Medicine, Winston-Salem, NC; Timmins et al., 2005). This
strain was backcrossed to C57BL/6 mice for more than 10 gen-
erations. To generate phagocyte-specific Scd1−/− mice, Scd1fl+/+
mice were intercrossed with C57BL/6J LysMCre mice, which were
kindly provided by G. van Loo (VIB-UGent Center for Inflam-
mation Research, University of Ghent, Ghent, Belgium; Vereecke
et al., 2014). To generate phagocyte-specific Abca1−/− mice,
Abca1fl+/+ mice were intercrossed with LysMCre mice. LXRα−/−,
LXRβ−/−, and LXRαβ−/− animals on a mixed 129/Sv and C57BL/6J
background (backcrossed for at least six generations) are de-
scribed in previous studies (Alberti et al., 2001; Schuster et al.,
2002). All mice were carefully genotyped by PCR as previously
described (Alberti et al., 2001; Miyazaki et al., 2007) or ac-
cording to protocols established by Jackson Laboratories. In all
experiments using knockout mice, littermates were used as
controls. For experiments using cell-specific knockout mice,
LysMCre+/−, Scd1fl+/+, and Abca1fl+/+ mice were used as controls.
For bone marrow isolation, myelin isolation, and brain slice
cultures, WT C57BL/6J mice were purchased from Envigo. Mice
were maintained on a 12-h light/dark cycle with free access to
water and either a standard chow diet or special formulations as
indicated. All animal procedures were conducted in accordance
with the institutional guidelines and approved by the Ethical
Committee for Animal Experiments of Hasselt University.
Myelin isolation and phagocytosis
Myelin was purified from postmortem mouse and human brain
tissue by means of density gradient centrifugation, as described
previously (Bogie et al., 2017). Myelin protein concentration was
determined by using the BCA protein assay kit (Thermo Fisher
Scientific), per the manufacturer’s guidelines. By using the
Chromogenic Limulus Amebocyte Lysate assay kit (Genscript),
endotoxin content of isolated myelin was determined to be neg-
ligible. To evaluate the ability and extent of myelin phagocytosis,
myelin was fluorescently labeled with 1,19-dioctadecyl-3,3,39,39-
tetramethylindocarbocyanine perchlorate (DiI; Sigma-Aldrich).
Cells were exposed to 100 µg/ml DiI-labeled myelin for 1.5 h and
analyzed for fluorescence intensity by using the FACSCalibur (BD
Biosciences). To define the uptake of latex beads, cells were ex-
posed to fluorescent red latex beads for 1.5 h (1:100, cat. no. L3030,
Sigma-Aldrich).
Macrophage, microglia, and astrocyte differentiation
and treatment
Mouse BMDMs andmicroglia were isolated and differentiated as
described previously (Bogie et al., 2017). For astrocytes, mixed
glial cells were isolated from pups (postnatal day 0–2). After
2 wk of cultivation, cultures were shaken for 16 h at 250 rpm and
37°C. After the shake-off procedure, the mixed glial cultures
were cultured in DMEMmedium enriched with 10% FCS and 1%
penicillin/streptomycin. Next, astrocytes were purified by dif-
ferential adhesion and mild trypsinization. BMDMs, microglia,
and astrocytes were plated at 0.5 × 106 cells/ml to be used for
in vitro experiments. Cells were treated daily with mouse my-
elin (100 µg/ml) for 24 h (mye24) or 72 h (mye72). To investigate
the involvement of downstream pathways, myelin treatment
was combined with CAY10566 (SCD1 inhibitor, 1 µM, Cayman
Chemicals), Rottlerin (PKCδ inhibitor, 3 µM, Sigma-Aldrich),
MβCD (2.5% m/v unless stated otherwise, Sigma-Aldrich), or
vehicle treatment for the indicated duration. For inflammatory
phenotyping, cells were subsequently stimulated with LPS
(100 ng/ml, Sigma-Aldrich) or IFN-G and IL-1B (100 ng/ml,
Peprotech) for 6 or 18 h for analysis of gene expression or pro-
tein abundance, respectively (Fig. S1 C). To test for SCD1 and
ABCA1 ablation, BMDMswere stimulatedwith T0901317 (10 µM,
LXR agonist, Cayman Chemicals) for 24 h before being lysed for
immunoblotting.
Human MDMs of healthy controls were isolated as described
previously (Bogie et al., 2017). Isolated CD14+ cells were differ-
entiated to macrophages in DMEM supplemented with 10%
human serum, 1% penicillin/streptomycin, and 1% L-glutamine.
After 6 d, adherent macrophages were harvested and plated at
0.3 × 106 cells/ml to be used for in vitro experiments. MDMs
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were treated daily with a dose of human myelin (10 µg/ml) for
24 h (mye24-MDMs) or 72 h (mye72-MDMs), combined with
CAY10566 (SCD1 inhibitor, 1 µM) or vehicle treatment. For
phenotyping, cells were stimulated with LPS (100 ng/ml) for 6 h
or 18 h to assess gene expression or protein level, respectively
(Fig. S1 C). All experimental protocols using human cells were
conducted in accordance with institutional guidelines and ap-
proved by the Medical Ethical Committee of Hasselt University.
Written informed consents were obtained from all individual
participants included in the study.
Cell line
HeLa-ABCA1gfp expressing GFP-labeled ABCA1 (HeLa-ABCA1gfp;
Neufeld et al., 2001) were cultured in DMEM supplementedwith
10% FCS and 1% penicillin/streptomycin.
FA treatment
Mouse BMDMs and HeLa-ABCA1gfp cells were treated with 1, 10,
or 50 µM of palmitoleic acid (16:1), oleic acid (18:1), 11-eicosenoic
acid (20:1), erucic acid (22:1), or nervonic acid (24:1) for 18 h.
Next, ABCA1 surface levels and extent of FA uptake were mea-
sured using flow cytometry. All FAs were purchased from
Sigma-Aldrich.
Immunoblotting
Cells were lysed in radioimmunoprecipitation assay buffer
(150 mM NaCl, 50 mM Tris, 1% SDS, 1% Triton X-100, and 0.5%
sodium deoxycholate) supplemented with protease-phosphatase
inhibitor cocktail (Roche). Samples were separated by electro-
phoresis on a 7% or 12% gel and were transferred onto a poly-
vinylidene fluoride membrane. Blots were blocked in 5%milk in
Tris-buffered saline, 0.5% Tween 20, and were incubated
overnight with relevant primary antibodies at 4°C, followed by
incubation with the appropriate HRP-conjugated secondary an-
tibody. An enhanced chemiluminescence plus detection kit
(Thermo Fisher Scientific) was used for detection. Densitometry
analysis was performed using ImageJ and normalized to actin.
Flow cytometry
Single-cell suspensions were blocked with 10% serum and
stained with relevant primary antibodies, followed by incuba-
tion with the appropriate secondary antibody. To assess cellular
viability, cells were incubated with 7AAD (Thermo Fisher Sci-
entific). The FACSCalibur was used to quantify cellular fluo-
rescence. Mean fluorescence intensity (MFI) was corrected for
background MFI.
Nitrite formation and TNF-A production
The release of NO and TNF-A was measured in supernatants
from cell cultures using a griess reagent system (Promega) and a
commercially available mouse TNF-A ELISA kit (eBioscience),
respectively. Both protocols were performed according to the
manufacturer’s instructions.
Immunofluorescence microscopy and image analysis
Mouse BMDMs and human MDMs were cultured on glass cover
slides and fixed in 4% PFA for 20 min. Cerebellar brain slices
were fixed in 4% PFA for 40 min. Frozen brain material from
activeMS lesions was obtained from the Netherlands Brain Bank
(Amsterdam, Netherlands). Clinical details of human brain tis-
sue are depicted in Table S1. Cryosections were fixed in acetone
for 10 min and in 70% ethanol for 5 min. Immunostaining and
analysis of fixed cells and cryosections were performed as de-
scribed previously (Bogie et al., 2017). To stain cerebellar brain
slices, samples were incubated with relevant primary antibody
diluted in blocking buffer (1× PBS + 1% BSA + 0.1% Triton X-100).
To visualize FC content, fixed cells were incubated with 50 µg/
ml Filipin III (Sigma-Aldrich) for 2 h at room temperature.
Analysis was performed using a Nikon Eclipse 80i microscope
and ImageJ software. The subdivision of the lesion rim and
center was accomplished by means of an ORO and proteolipid
protein (PLP) staining (rim, ORO+ cells and PLP+ extracellular
myelin; center, ORO+ cells and no PLP+ extracellular myelin).
Quantification of MFI was performed on original pictures
without image enhancement and normalized for background
MFI. Three-dimensional analysis of cerebellar brain slices was
done using the z-stack function on a LSM880 confocal micro-
scope (Zeiss), followed by three-dimensional rendering using
the vaa3d software (Peng et al., 2014). Pictures indicated in
figures are digitally enhanced.
ORO staining
To visualize EC, unfixed cryosections and fixed cells were
stained with 0.3% ORO (Sigma-Aldrich) for 10 min. Counter-
staining of cell nuclei was done using hematoxylin incubation.
Analysis was performed using a Leica DM 2000 LEDmicroscope
and ImageJ software.
Quantitative PCR
Tissue or cells were lysed using QIAzol (Qiagen). RNA was ex-
tracted using the RNeasy mini kit (Qiagen). Complementary
DNA was synthesized using the qScript cDNA synthesis kit
(Quanta Biosciences) according to the manufacturer’s in-
structions, and quantitative PCR was subsequently conducted
on a StepOnePlus detection system (Applied Biosystems). Data
were analyzed using the ΔΔCt method and normalized to the
most stable reference genes, as described previously (Nelissen
et al., 2010; Vandesompele et al., 2002). Primer sequences are
available on request.
Cholesterol measurement
Cholesterol efflux by FA-treated BMDMs was defined as de-
scribed previously (Song et al., 2015). Briefly, cells were exposed
to FAs (10 or 50 µM) for 18 h, after which they were labeled with
22-(N-nitrobenz-2-oxa-1,3-diazol-4-yl-amino)-23, 24-bisnor-5-
cholen-3-ol (NBD)–cholesterol (Invitrogen) for 4 h. To define
ABCA1-mediated efflux, cells were exposed to apoA-I (50 µg/ml;
Amar et al., 2010) in phenol- and serum-free medium for 4 h.
Intracellular NBD-cholesterol was assessed after cells were lysed
with 0.1% Triton X-100 for 30min. Fluorescence and absorbance
were measured using the FLUOstar OPTIMA microplate reader.
As myelin interfered with NBD-cholesterol fluorescence, cho-
lesterol efflux by myelin-treated BMDMs was measured by us-
ing The Amplex Red Cholesterol Assay Kit. For this purpose,
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BMDM and mye-BMDM cultures were exposed to apoA-I (50
µg/ml) in phenol- and serum-free medium for 4 h before mea-
suring intracellular and extracellular total cholesterol. Choles-
terol efflux was determined by dividing fluorescence in the
supernatants by the total fluorescence in supernatants and cells.
Transmission electron microscopy
Brain samples were fixed with 2% glutaraldehyde. Afterwards,
post-fixation was performed with 2% osmiumtetroxide in
0.05 M sodium cacodylate buffer for 1 h at 4°C. Dehydration of
the samples was performed by ascending concentrations of
aceton. The dehydrated samples were impregnated overnight in
a 1:1mixture of acetone and araldite epoxy resin. Afterwards, the
samples were embedded in araldite epoxy resin at 60°C and
were cut in slices of 70 nm, perpendicular to the CC, with a Leica
EM UC6 microtome and transferred to 0.7% formvar-coated
copper grids (Aurion). The samples were contrasted with 0.5%
uranyl acetate and lead citrate using a Leica EM AC20. Analysis
was performed with a Philips EM208 S electron microscope
(Philips) equipped with a Morada Soft Imaging System camera
with iTEM-FEI software (Olympus SIS). ImageJ was used to
calculate to g-ratio (the ratio of the inner axonal diameter to the
total outer diameter), using eight images/animal.
Mass spectrometry imaging (MSI)
Cryosections of active MS lesions were placed on indium tin
oxide–coated glass slides (Delta Technologies). Tissue sections
were coated with norharmane matrix (Sigma-Aldrich). Matrix
was prepared at 7 mg/ml in 2:1 CHCL3:MeOH (vol/vol) and ap-
plied to the tissue using a TM-Sprayer (HTX Technologies). MSI
was performed using an Orbitrap Elite mass spectrometer
(Thermo Fisher Scientific) coupled to an intermediate pressure
ion funnel matrix-assisted laser desorption/ionisation (MALDI)
source (Spectroglyph LLC; Belov et al., 2017). MSI data were
acquired at a pixel size of 40 × 40 µm2 at a nominal mass res-
olution of 240,000 (full-width half maximum at m/z 400). MSI
images were generated using in house developed software
written in MATLAB (MATLAB R2013a; Mathworks). For all data
shown, the corresponding [M+K]+ ions of the lipid of interest
were used to generate images and were normalized for the total
ion current. Mass accuracies were typically within 1 ppm of
theoretical m/z values after single point recalibration. Tandem
mass spectrometry was performed to determine acyl chain
compositions of PC lipid species containing two double bonds in
their sum-composition formula. Tandem mass spectrometry
was acquired from the corresponding [M+H]+ ions from lesion-
containing tissue regions using a mass isolation window of ±0.5
daltons, and higher-energy collisional dissociation.
ESI-MS/MS and GC-MS
Lipid extraction was performed based on a Bligh and Dyer
protocol. Briefly, cell pellets were reconstituted in 700 µl PBS,
800 µl CH3OH:HCL(1N) 8:1 (vol/vol), 900 µl CHCl3, and 200 µg/
ml of the antioxidant 2,6-di-tert-butyl-4-methylphenol (Sigma-
Aldrich). The organic fraction was evaporated using a Speedvac
at RT and the remaining lipid pellet was stored under argon at
–20°C. Prior to mass spectrometry analysis, lipid pellets were
dissolved in running solution (NH4OH:CHCl3:CH3OH; 1.25:10:
90; vol/vol/vol). Phospholipids were analyzed by ESI-MS/MS on
a hybrid triple quadrupole/linear ion trap mass spectrometer
(4000 QTRAP system; SCIEX) equipped with a robotic nano-
source for automated sample injection and spraying (TriVersa
NanoMate, Advion Biosciences). Phospholipid profiling was
executed in positive ionmode by a precursor ion scan (184.1) for
PC at a collision energy of 50 eV. Phospholipid quantification
was performed in multiple reactions monitoring mode with a
signal averaging period of 3 min. Lipid standards PC25:0 and
PC43:6 (Avanti Polar Lipids) were added based on the amount of
protein in the original sample. Protein concentration was
measured using the Pierce BCA Protein Assay Kit (Thermo
Fisher Scientific). The data were corrected for hydrogen, ni-
trogen, carbon, and oxygen isotope effects using the algorithm
described by Liebisch et al. (2004). Only lipid species with a
signal intensity of at least five times the blank were reported.
GC-MS analysis of hydrolyzed FAs derived from BMDM cultures
was performed as described previously (Carnielli et al., 1994).
Cuprizone-induced acute demyelination in vivo model
To induce acute demyelination, 9–11-wk-old male mice were fed
ad libitum a diet of 0.3% cuprizone (bis[cyclohexanone]ox-
aldihydrazone, Sigma-Aldrich) mixed in powdered standard
chow for 6 wk. The control group consisted of aged-matched
male mice that were fed normal chow. Upon withdrawal of
the cuprizone diet, spontaneous remyelination occured. After
1 wk of recovery, tissue was collected for histological and bio-
chemical analysis (Fig. S4 B).
Cerebellar slice cultures
Cerebellar slices were obtained from C57BL/6 mouse pups at the
age of P9 or P10, as described previously (Hussain et al., 2011;
Meffre et al., 2015). To induce demyelination, slices were treated
with lysolecithin (0.5 mg/ml; Sigma-Aldrich) for 16 h. After
demyelination, slices were treated daily with CAY10566 (SCD1
inhibitor, 10 µM) or vehicle for 1 wk, followed by histological
and biochemical analysis (Fig. S4 A).
Statistical analysis
Data were statistically analyzed using GraphPad Prism and are
reported as mean ± SEM. The D’Agostino and Pearson omnibus
normality test was used to test for normal distribution. When
datasets were normally distributed, an ANOVA (Tukey’s post
hoc analysis) or two-tailed unpaired Student’s t test (with
Welch’s correction if necessary) was used to determine statis-
tical significance between groups. If datasets did not pass nor-
mality, the Kruskal–Wallis or Mann–Whitney analysis was
applied. P values <0.05 were considered to indicate a significant
difference (*, P < 0.05, **, P < 0.01, and ***, P < 0.001).
Online supplemental information
Fig. S1 shows changes in SCD1 activity and the inflammatory
phenotype of phagocytes upon myelin internalization. Fig. S2
shows functional and morphological changes associated with
inhibition of SCD1 in foamy phagocytes. Fig. S3 shows the forma-
tion of ABCA1-destablizing FAs upon intracellular accumulation of
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myelin. Fig. S4 shows brain pathological parameters in cuprizone-
fed Scd1fl+/+LysmCre+mice. Fig. S5 shows improved remyelination in
whole-body SCD1-deficient mice. Table S1 shows clinical details of
human brain tissue used in this manuscript.
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Figure S1. Sustained exposure to myelin promotes an inflammatory phagocyte phenotype and induces SCD1 abundance and activity. (A and B)
Representative images of ORO (EC) and CD68/filipin (FC) staining of NAWM of control brain tissue (n = 2 nonneurological controls). Scale bar, 100 µm. (C)
Experimental setup of mouse BMDM, mouse microglia, and humanMDM experiments. (D) Viability of BMDMs, microglia, and MDMs treated with myelin for 24
or 72 h (n = 4 wells). Dotted line represents untreated cells. (E) mRNA expression of inflammatory factors in IFN-G/IL-1B–stimulated BMDMs (n = 5 wells),
microglia (n = 6 wells), and MDMs (n = 6 wells) treated with myelin for 24 or 72 h, or left untreated (dotted line, Ctrl). (F) Representative images of untreated
(Ctrl) and myelin-treated (24 and 72 h) BMDMs, microglia, and MDMs stained for SCD1. (G) Flow-cytometric analysis of SCD1 in WT, LXRα−/−, LXRβ−/−, and
LXRα−/−LXRβ−/− BMDMs treated with myelin for 72 h (n = 5 wells). Dotted line represents untreated BMDMs. (H and I) Quantification of the percent of
phagocytes expressing SCD1 within the phagocyte pool and the percent of phagocytes expressing SCD1 within the SCD1+ cell pool of active MS lesions stained
for SCD1/IBA1 (n = 3 lesions from three different MS patients). (J) Representative mass spectrometry images of individual intact PC lipid species (PC36:2 and
PC36:1) in active MS lesions (ratio is depicted in Fig. 3 G). Data are represented as normalized intensity. Mass error is depicted in parts per million (ppm). (K)
Mass spectrometry image of the ratio of intact PC lipid species and corresponding ORO staining of a second active MS lesion. The PC36:2/PC36:1 ratio was
calculated based on intensity images of individual PC lipid species. Scale bar, 500 µm. (L) Representative mass spectrometry images of PC36:2 and PC36:1 in
the second active MS lesion. Data are represented as normalized intensity. Mass error is depicted in parts per million. Results are pooled from or representative
of two (A, B, D–F, and J–L) and three (H and I) independent experiments . For human MDM cultures, three (E) and four (D) donors were used. All data are
represented as mean ± SEM. *, P < 0.05, **, P < 0.01, and ***, P < 0.001 unpaired Student’s t test (A and E), one-way ANOVA (G–I).
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Figure S2. The impact of SCD1 on the physiology of mye-phagocytes. (A) ESI-MS/MS–based lipidomics analysis of intact PC in mye72-BMDMs treated
with an SCD1 inhibitor or vehicle (n = 2 wells). (B) Relative gene expression of neurotrophic factors in LPS-stimulated mye72-BMDMs (n = 5 wells), -microglia
(n = 6 wells), and -MDMs (n = 4 wells) treated with an SCD1 inhibitor or vehicle (tumor growth factor β [Tgfb], insulin growth factor 1 [Igf1], ciliary neurotrophic
factor [Cntf]). (C) Viability of BMDMs (n = 10 wells), microglia (n = 6 wells), and MDMs (n = 8 wells) exposed to an SCD1 inhibitor or vehicle. (D) Uptake of
fluorescently-labeled myelin (n = 4–6 wells) and beads (n = 4 or 5 wells) by BMDMs, microglia, and MDMs treated with an SCD1 inhibitor or vehicle (Ctrl).
(E) Representative transmission electron microscopy images of untreated BMDMs (Ctrl), mye72-BMDMs, and mye72-BMDMs treated with an SCD1 inhibitor
(n = 4 wells, 5 cells/well were analyzed). Blue arrowheads and arrows point to lipid droplets and myelin-containing organelles (mye-organelles), respectively.
Scale bar, 5 µm. (F and G) Quantification of the number and size of lipid droplets and mye-organelles in untreated BMDMs (Ctrl), mye72-BMDMs, and mye72-
BMDMs treated with an SCD1 inhibitor (n = 4 wells, 5 cells/well were analyzed). Results are pooled from or representative of two (A–G) independent ex-
periments. For human MDM cultures, four donors were used (B–D). All data are represented as mean ± SEM. *, P < 0.05, **, P < 0.01, and ***, P < 0.001,
unpaired Student’s t test (B–D), one-way ANOVA (F and G).
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Figure S3. Sustained myelin internalization increases the formation of ABCA1-destablizing FAs and promotes inflammatory cholesterol accumu-
lation. (A) ABCA1 abundance in HeLa-ABCA1gfp cells treated with myelin for 24 or 72 h, or left untreated (Ctrl, n = 6 wells). (B) Uptake of fluorescently labeled
myelin (myelinDiI) by HeLa-ABCA1gfp cells (n = 4 wells). (C and D) Representative images and quantification (percent cell area covered with lipid droplets) of
ORO (EC) staining of myelin-treated HeLa-ABCA1gfp cells. Scale bar, 20 µm (n = 2 wells). (E and F) GC/MS analysis of the methyl esters of FAs hydrolyzed from
untreated (Ctrl) and myelin-treated BMDMs (24 or 72 h, n = 4 wells). (G) Relative uptake of MUFAs (1, 10, and 50 µM), determined by measuring the SSC (n = 3
wells). (H) ABCA1 abundance in HeLa-ABCA1gfp cells treated with MUFAs for 24 h (1, 10, and 50 µM; n = 4 wells). (I) Surface ABCA1 abundance on myelin-
treated (24 h) mouse BMDMs (n = 5 wells), mouse microglia (n = 6 wells), and human MDMs (n = 4 wells) exposed to rottlerin (PKCδ inhibitor) or vehicle. (J and
K) Immunoblot analysis of ABCA1 protein levels inWT and Abca1fl+/+LysmCre+/− BMDMs stimulated with the LXR agonist T0901317 (n = 2/3 cultures of different
animals). (L) Viability of WT and Abca1−/−-BMDMs exposed to myelin for 72 h (n = 4 wells). (M and N) Cholesterol content (n = 7 wells) and viability (n = 7 wells)
of mye72-BMDMs exposed to MβCD (1, 2.5, and 5% m/v) or vehicle. Results are pooled from or representative of two (A–J, M, and N) and three (K and L)
independent experiments. For human MDM cultures, four donors were used (I). All data are represented as mean ± SEM. *, P < 0.05, **, P < 0.01, and ***, P <
0.001, one-way ANOVA (A, D–H, M, and N), unpaired Student’s t test (B, K, and L).
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Figure S4. Confirmation of SCD1 ablation and pathological parameters of Scd1fl+/+LysmCre+ mice. (A and B) Experimental setup of the brain slice culture
model for remyelination (A) and cuprizone-induced acute demyelination in vivo model (B). SCD1 inh., SCD1 inhibitor. (C) Immunoblot analysis of SCD1 protein
in WT, Scd1fl+/+LysmCre+/−, and Scd1−/− BMDMs stimulated with the LXR agonist T0901317 (n = 2 cultures of different animals). (D and E) Representative
immunofluorescence images and quantification of F4/80 staining of CC from WT (6 wk, n = 11 animals; 6+1 wk, n = 10 animals) and Scd1fl+/+LysMCre+/− mice
(6 wk, n = 7 animals; 6+1 wk, n = 6 animals). Scale bar, 100 µm. (F and G)mRNA expression of neurotrophic factors in CC of WT (6 w, n = 11 animals; 6+1 wk,
n = 10 animals) and Scd1fl+/+LysMCre+/− mice (6 w, n = 7 animals; 6+1 wk, n = 6 animals) after cuprizone-induced demyelination (6 w) and subsequent re-
myelination (6+1 wk). All replicates were biologically independent. All data are represented as mean ± SEM. **, P < 0.01, unpaired Student’s t test (E–G).
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Figure S5. Whole-body Scd1 deficiency improves remyelination in the cuprizone model. (A) Representative images of immunofluorescence MBP staining
and TEM analysis of CC derived fromWT and Scd1−/−mice after cuprizone-induced demyelination (6 wk) and subsequent remyelination (6+1 wk; n = 5 animals/
group). Scale bars, 100 µm (MBP staining); 2 µm (TEM). (B) Quantification of the remyelination efficacy (calculated by dividing the percent myelination at 6+1
wk by the percent myelination at 6 wk using the MBP staining) in CC from WT and Scd1−/− mice (n = 5 animals/group). (C and D) Analysis of the g-ratio (the
ratio of the inner axonal diameter to the total outer diameter) and g-ratios as a function of axon diameter in CC fromWT (6 wk, n = 4 animals; 6+1 wk, n = 2 animals)
and Scd1−/− mice (6 wk, n = 4 animals; 6+1 wk, n = 2 animals). (E and F)mRNA expression inflammatory mediators in CC of WT and Scd1−/− mice after 6 wk (n = 5
animals) and 6+1 wk (n = 9 animals). Gene expression was corrected for the number of F4/80+ phagocytes. (G) Representative images of F4/80, ORO (EC), and
ABCA1 staining of CC from WT and Scd1−/− mice after cuprizone-induced demyelination (6 wk, n = 5 animals/group) and subsequent remyelination (6+1 wk, n = 5
animals/group). Scale bar, 100 µm. (H–K) Quantification of F4/80 staining, ORO staining (lipid load defined as percent ORO+ area of total CC area, lipid load
corrected for number of F4/80+ macrophages), and ABCA1 staining (% ABCA1+ area of total CC area; n = 5 animals/group). (L and M) mRNA expression of neu-
rotrophic factors in CC of WT and Scd1−/− mice after cuprizone-induced demyelination (6 wk, n = 5 animals/group) and subsequent remyelination (6+1 wk, n = 9
animals/group). All replicateswere biologically independent. All data are represented asmean ± SEM. *, P < 0.05, and **, P < 0.01, unpaired Student’s t test (B, E, F, L,
and M), one-way ANOVA (C and H–K).
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Table S1 is provided online as a separate Word document and lists clinical details of human brain tissue.
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